Dalpiciclib in HR+/HER2- ABC
Recruiting
Observational Study
Advanced Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 103 (estimated)
- Sponsor
- RenJi Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed advanced breast cancer
* Hormone receptor-positive and human epidermal growth factor receptor 2-negative
* ECOG 0-1
Exclusion Criteria:
* Pregnant or breastfeeding
* History of immunodeficiency
Contacts